| BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors (NCT07469774) | Biocity Biopharmaceutics Co., Ltd. | 2026-03-31 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of BC2027 in Patients With Advanced Solid Malignancies (NCT07368478) | Biocity Biopharmaceutics Co., Ltd. | 2025-11-24 |
| A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria (NCT06819826) | Biocity Biopharmaceutics Co., Ltd. | 2025-02-14 |
| A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of BC3195 in Patients With Advanced or Metastatic Cancer (NCT06548672) | Biocity Biopharmaceutics Co., Ltd. | 2024-06-24 |
| SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer (NCT06055348) | Biocity Biopharmaceutics Co., Ltd. | 2023-10-30 |
| BC3402 in Combination With Durvalumab in Patients With Advanced Hepatocellular Carcinoma (NCT06111326) | Biocity Biopharmaceutics Co., Ltd. | 2023-10-01 |
| A Phase I Study of BC3402 as a Single Agent in Patients With MDS and CMML (NCT05690425) | Biocity Biopharmaceutics Co., Ltd. | 2023-07-06 |
| Study of BC3195 Monotherapy in Patients With Advanced Solid Tumors (NCT05957471) | Biocity Biopharmaceutics Co., Ltd. | 2023-06-26 |
| Study of BC3402 in Combination With Azacitidine in Patients With MDS and CMML (NCT05970822) | Biocity Biopharmaceutics Co., Ltd. | 2023-06-18 |
| A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney Disease (NCT05687890) | Biocity Biopharmaceutics Co., Ltd. | 2023-05-23 |
| SC0245 and Irinotecan in Treating Patients With Relapsed Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (NCT05731518) | Biocity Biopharmaceutics Co., Ltd. | 2023-02-23 |